✦ LIBER ✦

CO2 ACCOUNTING FOR THE DRUG LIFE CYCLE AND FUTURE DRUG PRICES IN COST EFFECTIVENESS ANALYSIS

✍ Scribed by M Hoyle

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The future role of NICE: Value based pri

✍ Alan Maynard and Karen Bloor 📂 Article 📅 2010 🏛 BMJ Publishing Group 🌐 English ⚖ 464 KB

PMD82 Drug Eluting Balloon for the Treat

✍ S. Giardina; P. Brasseur; R. Busca; A. Micari 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost-Effectiveness Analysis of Oseltamiv

✍ Hiroko Nagase; Kensuke Moriwaki; Maki Kamae; Shinichiro Yanagisawa; Isao Kamae 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PIN18 COST-EFFECTIVENESS ANALYSIS OF OSE

✍ H Nagase; M Kamae; K Moriwaki; S Yanagisawa; I Kamae 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PGS11 USING A COST-UTILITY ANALYSIS FOR

✍ P Wahlqvist 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PSR2 EVALUATING THE POTENTIAL COST-EFFEC

✍ T Arant; P Sullivan 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB